(PHA) Premier Health of America - Ratings and Ratios
Exchange: V • Country: Canada • Currency: CAD • Type: Common Stock • ISIN: CA74052G1063
PHA: Healthcare Staffing, Staffing Services, Health Consulting, Healthcare Services
Premier Health of America Inc. is a Canadian healthcare staffing and outsourced services provider, operating through two main segments: Per Diem and Travel Nurse. The company delivers temporary or permanent healthcare resources, including registered nurses, therapists, and personal support workers, to various healthcare facilities, such as hospitals, clinics, and retirement homes. Additionally, Premier Health offers specialized healthcare services in remote communities, including health consulting and nursing services. Their services are facilitated through PSweb, a proprietary CRM platform, and cater to governments, corporations, and individuals. With its headquarters in Blainville, Canada, the company is poised to capitalize on the growing demand for healthcare staffing solutions.
Analyzing the companys financial and technical data, we observe a currently undervalued stock with a market capitalization of $5 million CAD. The stocks price is hovering around $0.07, significantly lower than its 52-week high of $0.40. The short-term moving averages (SMA20 and SMA50) indicate a stable trend, while the long-term SMA200 suggests a potential for recovery. The Average True Range (ATR) of 0.01 represents a 10.48% volatility, indicating a relatively stable stock. The absence of a P/E ratio and a negative Return on Equity (RoE) of -215.13% suggest that the company is currently unprofitable.
Forecasting the stocks performance, we can infer that the current price is likely to be influenced by the companys future earnings reports and the overall healthcare industry trends. Given the growing demand for healthcare staffing services, Premier Health is well-positioned to capitalize on this trend. However, the companys current unprofitability and high forward P/E ratio of 35.97 may indicate potential risks. Based on the technical data, a potential price target could be around $0.12-$0.15, representing a 70-100% increase from the current price, assuming the company can achieve profitability and improve its financial performance. Nevertheless, this forecast is subject to significant uncertainty and requires careful monitoring of the companys progress.
Additional Sources for PHA Stock
PHA Stock Overview
Market Cap in USD | 3m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Facilities |
IPO / Inception |
PHA Stock Ratings
Growth Rating | -86.6 |
Fundamental | -28.3 |
Dividend Rating | 0.0 |
Rel. Strength | -80.8 |
Analysts | - |
Fair Price Momentum | 0.05 CAD |
Fair Price DCF | 0.27 CAD |
PHA Dividends
Currently no dividends paidPHA Growth Ratios
Growth Correlation 3m | 16.4% |
Growth Correlation 12m | -79.2% |
Growth Correlation 5y | -81.2% |
CAGR 5y | -35.89% |
CAGR/Max DD 5y | -0.37 |
Sharpe Ratio 12m | -0.03 |
Alpha | -88.28 |
Beta | 0.128 |
Volatility | 141.01% |
Current Volume | 20k |
Average Volume 20d | 16.5k |
As of June 23, 2025, the stock is trading at CAD 0.07 with a total of 20,000 shares traded.
Over the past week, the price has changed by +0.00%, over one month by -7.14%, over three months by -13.33% and over the past year by -82.43%.
Probably not. Based on ValueRay´s Fundamental Analyses, Premier Health of America (V:PHA) is currently (June 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.28 and therefor a somewhat negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PHA is around 0.05 CAD . This means that PHA is currently overvalued and has a potential downside of -28.57%.
Premier Health of America has no consensus analysts rating.
According to our own proprietary Forecast Model, PHA Premier Health of America will be worth about 0.1 in June 2026. The stock is currently trading at 0.07. This means that the stock has a potential downside of -14.29%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 0.2 | 185.7% |
Analysts Target Price | - | - |
ValueRay Target Price | 0.1 | -14.3% |